Bayer to make $10.5 billion push to settle Roundup cases

Published: Tuesday, February 17, 2026 at 5:38 pm

Bayer to Offer $10.5 Billion to Settle Roundup Lawsuits

Bayer AG is reportedly preparing to announce a significant financial commitment to resolve ongoing and future cancer lawsuits related to its Roundup weedkiller. According to sources familiar with the plan, the German company intends to allocate $10.5 billion to address the litigation.

The proposed settlement includes a $7.5 billion class-action settlement aimed at resolving existing and potential Roundup lawsuits filed in state courts. This settlement is designed to cover claims that have already been filed, as well as potential future claims over a 20-year period.

In addition to the class-action settlement, Bayer is also poised to announce $3 billion in settlements for existing US cases. These cases involve former Roundup users who allege the herbicide caused their non-Hodgkin's lymphoma.

The news of the settlement plan led to a positive reaction in the market, with Bayer's shares experiencing a notable increase.

The Roundup litigation has been a major challenge for Bayer since its acquisition of Monsanto. The company inherited a large number of lawsuits alleging that Roundup, and its active ingredient glyphosate, caused cancer. Bayer has already paid out over $10 billion in verdicts and settlements related to the herbicide. Despite these payouts, Bayer still faces approximately 67,000 claims from plaintiffs who allege that long-term exposure to glyphosate caused their cancer. Bayer maintains that the weedkiller is safe, citing findings from the US Food and Drug Administration.

The decision to pursue this settlement comes after the US Supreme Court agreed to hear Bayer's appeal of a previous jury verdict. The litigation has become a significant concern for the company, with the CEO considering the possibility of discontinuing the production of glyphosate altogether.

BNN's Perspective:

While this settlement represents a substantial financial commitment by Bayer, it also highlights the ongoing challenges the company faces regarding the safety of Roundup. The settlement, if finalized, could provide some relief to those affected by the litigation. However, the long-term implications for Bayer and the future of glyphosate remain uncertain.

Keywords: Bayer, Roundup, settlement, lawsuits, glyphosate, cancer, non-Hodgkin's lymphoma, Monsanto, weedkiller, litigation, class-action, US Supreme Court

Full Story